Health Insurance (Section 3C Co-Dependent Pathology Services) Amendment Determination 2018 (Cth)

Health Insurance (Section 3C Co-Dependent Pathology Services) Amendment Determination 2018

I, CELIA STREET, delegate of the Minister for Health, make the following determination.

Dated              25 October 2018

Celia Street

Assistant Secretary

Diagnostic Imaging and Pathology Branch

Medical Benefits Division

Department of Health

Contents

1.Name  3

2.Commencement  3

3.Authority  3

4.Schedules  3

Schedule      1 – Amendment   4

1. Name

This determination is the Health Insurance (Section 3C Co-Dependent Pathology Services) Amendment Determination 2018.

1. Commencement

(1)     Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1.  The whole of this instrument	1 November 2018

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2)  Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

1. Authority

This Instrument is made under subsection 3C(1) of the Health Insurance Act 1973.

1. Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1 – Amendment

Health Insurance (Section 3C Co-Dependent Pathology Services) Determination 2018

1  Schedule 1 (at the beginning of the table)

Add:

73288 Immunohistochemical examination by immunoperoxidase or other labelled antibody techniques using the programmed cell death ligand 1 (PD-L1) antibody of tumour material from a patient diagnosed with non-small cell lung cancer, to determine if the requirements relating to PD-L1 status for access to pembrolizumab under the Pharmaceutical Benefits Scheme are fulfilled. 74.50